Delcath Systems Q2 revenue rises, beats estimates

Delcath Systems

06/08/2026 13:16

Overview
US interventional oncology firm's Q2 revenue rose, beating analyst expectations
Net income for Q2 was flat yr/yr at $2.7 mln
Company raised 2026 revenue guidance to $104 mln-$108 mln

Outlook
Delcath Systems raises 2026 revenue guidance to $104 mln-$108 mln
Company expects full-year gross margins of 86%-89%
Delcath Systems anticipates positive adjusted EBITDA for 2026

Result Drivers
HEPZATO VOLUME GROWTH - Co reported approximately 30% growth in HEPZATO volume in Q2 2026 vs Q2 2025
TREATMENT CENTER EXPANSION - Co said growth in active treatment center network and physician adoption drove increased HEPZATO usage
CLINICAL TRIAL ACTIVITY - Co attributed higher R&D expenses to increased clinical headcount and clinical trial activity

Company press release: ID:nBwbGbkFHa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$29.13 mln
$26.26 mln (5 Analysts)
Q2 EPS
 
$0.07
 
Q2 Net Income
 
$2.67 mln
 
Q2 Gross Profit
 
$26.15 mln
 
Q2 Operating Expenses
 
$23.75 mln
 
Q2 Operating Income
 
$2.40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Delcath Systems Inc is $21.50, about 70.2% above its August 5 closing price of $12.63

Reuters Recommended Reads
Aug 5 - Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Aug 5 - Biodesix Q2 revenue rises 34%, beats analyst estimates
Aug 4 - Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)